SOLOMON FISCH, M.D., PH.D., F A.C.P.
This content is PDF only. Please click on the PDF icon to access.
To the editor: May I contribute this practice-derived addendum to the editorial on phenformin by Drs. Williams and Palmer (Ann Intern Med 83:567-568, 1975)? In all that I have read on this controversial subject, I have not seen this hazard mentioned.
A persistent drawback, rather than an advantage, of the oral hypoglycemics is that they represent a "convenient" alternative to insulin for the nonketotic patient. But whenever a diabetic cannot be regulated by maximal doses of these drugs, the simple mention of insulin makes some patients run to the hills, while others go into hysterical attacks that require multiple subsequent
FISCH S. Phenformin. Ann Intern Med. ;84:103. doi: 10.7326/0003-4819-84-1-103_2
Download citation file:
Published: Ann Intern Med. 1976;84(1):103.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use